Prospective, multicentre, randomised controlled trial comparing the seroclearance of HBsAg between combination therapy of peg-interferon alpha and tenofovir with tenofovir monotherapy in nucleos(t)ide analogue-experienced patients with HBV-related liver fibrosis: a study protocol by Jianguo Li, Xuejun Li, Jing Yuan, Zhihua Liu, Liang Peng, Lina Wu, Shu Zhu, Yongyu Mei, Luping Lin

“…This study was designed to compare the efficacy between peg-IFN alpha combined with tenofovir (TDF) and TDF monotherapy for the clearance of HBsAg in NA-experienced patients with HBV-related liver fibrosis.Methods and analysis This study was designed to be a prospective, multicentre, open, randomised controlled study. …”
Get full text

Distinct Lipidomic Profiles between People Living with HIV Treated with E/C/F/TAF or B/F/TAF: An Open-Label Prospective Cohort Study by Zhikai Wan, Junwei Su, Xueling Zhu, Xiang Liu, Yongzheng Guo, Dairong Xiang, Xiaotang Zhou, Xiaorong Peng, Ran Tao, Qing Cao, Guanjing Lang, Ying Huang, Biao Zhu

Subjects: “…Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide…”
Get full text

Kidney disease among adults on tenofovir-based second-line antiretroviral therapy in Dar es Salaam, Tanzania by Sabina F. Mugusi, Grace A. Shayo, Philip G. Sasi, Lulu S. Fundikira, Eric A. Aris, Christopher R. Sudfeld, Ferdinand M. Mugusi

Subjects: Get full text

Phase 1 randomized pharmacokinetic and safety study of a 90‐day tenofovir vaginal ring in the United States by Albert Y. Liu, Holly Gundacker, Barbra Richardson, Beatrice A. Chen, Craig Hoesley, Ariane van derStraten, Amanda Brown, May Beamer, Jennifer Robinson, Cindy E. Jacobson, Rachel Scheckter, Katherine Bunge, Jill Schwartz, Andrea Thurman, Jeanna M. Piper, Mark A. Marzinke, the MTN‐038 Protocol Team for the Microbicide Trials Network

Subjects: “…tenofovir…”
Get full text

Factors Affecting Rapid Decline in Glomerular Filtration Rate in HIV/AIDS Patients Using Tenofovir Disoproxil Fumarate by Prima Yuriandro, Evy Yunihastuti, Maruhum Bonar H. Marbun, Pringgodigdo Nugroho

Subjects: Get full text

Rapid stability-indicating UHPLC method for determination of lamivudine and tenofovir disoproxil fumarate in fixed-dose combination tablets by Danielle Evangelista Rabelo de Souza, Nicoly Kaliny Magela Gomes, Gerson Antônio Pianetti, Bruno Gonçalves Pereira, Christian Fernandes

“…Lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) are antiretroviral drugs widely used for AIDS treatment. …”
Get full text

A Retrospective Cohort Study on the Risk of Kidney Disease in HIV Positive Individuals Receiving Tenofovir Based Regimens by Vikash Khandelia, Umashankar Nama, Ashok Mahavar, Anjali Rathore

“…Introduction: Exposure to tenofovir often leads to the development of some irreversible high risk for kidney disease events. …”
Get full text

Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring. by Viktor von Wyl, Valentina Cambiano, Michael R Jordan, Silvia Bertagnolio, Alec Miners, Deenan Pillay, Jens Lundgren, Andrew N Phillips

“…BACKGROUND: The most recent World Health Organization (WHO) antiretroviral treatment guidelines recommend the inclusion of zidovudine (ZDV) or tenofovir (TDF) in first-line therapy. We conducted a cost-effectiveness analysis with emphasis on emerging patterns of drug resistance upon treatment failure and their impact on second-line therapy. …”
Get full text

Reply to “Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy” by Meng-Ju Lin, Tung-Hung Su, Jia-Horng Kao

Get full text

Effectiveness of switching to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV with historical drug resistance mutations by Ziwei Chang, Hongyan Zhu, Yiting Zhang, Yaling Chen, Jiahui Li, Jiamin Qin, Yueping Zhu, Hongxia Wei, Yongfeng Yang, Meiyin Zou, Feng Qian, Zhiliang Hu, Yanjie Yin

Get full text

Estimated glomerular filtration rate partially recovered in patients without Hypertriglyceridemia during Tenofovir disoproxil fumarate treatment by Ya-ru Pan, Si-qi Liu, Yi-shan He, Yuan Xue, Jian Wang, Rui Huang, Chao Wu, Jian-chun Lu, Long-gen Liu

Subjects: “…Tenofovir disoproxil fumarate…”
Get full text

Rapid stability-indicating UHPLC method for determination of lamivudine and tenofovir disoproxil fumarate in fixed-dose combination tablets by Danielle Evangelista Rabelo de Souza, Nicoly Kaliny Magela Gomes, Gerson Antônio Pianetti, Bruno Gonçalves Pereira, Christian Fernandes

“…Lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) are antiretroviral drugs widely used for AIDS treatment. …”

Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection by Isabella Zanella, Daniela Zizioli, Francesco Castelli, Eugenia Quiros-Roldan

Subjects: “…tenofovir…”
Get full text

Rapid stability-indicating UHPLC method for determination of lamivudine and tenofovir disoproxil fumarate in fixed-dose combination tablets by Danielle Evangelista Rabelo de Souza, Nicoly Kaliny Magela Gomes, Gerson Antônio Pianetti, Bruno Gonçalves Pereira, Christian Fernandes

“…Lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) are antiretroviral drugs widely used for AIDS treatment. …”
Get full text

Acute Renal Failure in Four HIV-Infected Patients: Potential Association with Tenofovir and Nonsteroidal Anti-Inflammatory Drugs by Suzanne Marcotte Bpharm, Annie Talbot, Benoît Trottier

Get full text

Tenofovir-Diphosphate as a Marker of HIV Pre-exposure Prophylaxis Use Among East African Men and Women by Maria Pyra, Maria Pyra, Pete Anderson, Jessica E. Haberer, Jessica E. Haberer, Renee Heffron, Renee Heffron, Connie Celum, Connie Celum, Connie Celum, Stephen Asiimwe, Elly Katabira, Nelly R. Mugo, Nelly R. Mugo, Elizabeth A. Bukusi, Elizabeth A. Bukusi, Elizabeth A. Bukusi, Jared M. Baeten, Jared M. Baeten, Jared M. Baeten

Subjects: “…tenofovir-diphosphate…”
Get full text

Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine. by Allison Martin, Janaki Amin, Sean Emery, David Baker, Andrew Carr, David A Cooper, Mark Bloch, STEAL Study Group

“…We examined predictors of anthropometric outcomes over 96 weeks in HIV-infected, lipoatrophic adults receiving stable cART randomised to tenofovir-emtricitabine (TDF-FTC) or abacavir-lamivudine (ABC-3TC) fixed dose combinations.The STEAL study was a prospective trial of virologically suppressed participants randomised to either TDF-FTC (n = 178) or ABC-3TC (n = 179). …”
Get full text

Tenofovir versus entecavir on recurrence and mortality of hepatitis B virus-related hepatocellular carcinoma after curative therapy by Kai-Chun Chang, Tung-Hung Su, Sih-Han Liao, Tai-Chung Tseng, Shang-Chin Huang, Shih-Jer Hsu, Chun-Ming Hong, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao

“…Background: Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) reduce the risk of hepatocellular carcinoma (HCC) in patients of hepatitis B. …”
Get full text

Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir. by Christine Njuguna, Catherine Orrell, Richard Kaplan, Linda-Gail Bekker, Robin Wood, Stephen D Lawn

“…Patterns of drug substitutions and regimen switches from stavudine (d4T) and zidovudine (AZT) regimens have been well described but data on tenofovir (TDF) are more limited. This study describes the patterns and risk factors for drug changes of these antiretroviral drugs in adults.This retrospective cohort study included HIV positive, antiretroviral treatment (ART) naïve adults aged ≥18 years who started ART with two nucleoside reverse transcriptase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor. …”
Get full text

Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response? by Byoung Kuk Jang

Subjects: Get full text